Innovative Targeting Solutions Builds Momentum with a Key Milestone and a New Collaborator

January 5th, 2015: Innovative Targeting Solutions (ITS) has successfully achieved its first milestone with its collaboration with Amgen and is excited to announce a new collaboration with another major international pharmaceutical company. The company is also in active discussions with other potential collaboration partners that it expects to have completed in the first half of 2015. Commenting on the new collaboration momentum, Michael Gallo, ITS’ President, “I think initially ITS was just seen as another antibody technology and people did not understand the technology’s versatility and capabilities. We garnered much more attention when we started generating fully human antibodies to GPCRs and especially when we generated an agonist to the GLP-1 receptor. Our ability to easily transition to heavy chain only antibodies (HCAbs) also was an attractive feature of the platform making it straight forward to generate bispecifics and dual agonist molecules. The ability to engineer proteins in a mammalian system provides for opportunities not possible with traditional yeast or phage display and this makes us much more than just another antibody technology, this makes us a leader in the generation of novel Biologics.”

About Innovative Targeting Solutions Inc. Founded in 2008, Innovative Targeting Solutions Inc. is a privately‐held company that has developed the HuTARG technology a next generation protein engineering platform for the generation and maturation of fully human antibody therapeutics. The HuTARG technology is a fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information please visit

ITS Announcement 2015-01-05